Synfini
Address: Menlo Park, California.About Us
Synfini, Inc., a privately held Menlo Park, California-based company, is a pioneer in agile chemistry. Its advanced, automated molecular discovery platform is transforming drug discovery through integrated neuro-symbolic AI, discovery-focused robotic automation, and world-class chemistry data. The patented Synfini platform includes automated chemical synthesis technologies from SRI International. As a commercial enterprise Synfini will provide accelerated molecular discovery to drug hunters and. pharmaceutical companies worldwide.
Sectors
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Services
- Software Services
Categories
- Drug Discovery Services
- Drug Development Services
- Drug Design
- Software
- Software-AI
- Software-Process
- Chemistry Services
- Medicinal Chemistry
- Chemical Libraries
- Automation Technology
- Process Development
- Small Molecules
- Hit-to-Lead
- Lead Compound Optimisation
News
Synfini Inc. and O2nix Bio Announce Strategic Collaboration to Develop Novel Cancer Therapeutics Targeting FTSJ1
June 17, 2025 – Menlo Park, CA & Cambridge, MA – Synfini Inc., a leader in AI-driven drug discovery, and O2nix Bio, a pioneering biotech company advancing prooxidant therapies, today announced a strategic collaboration to co-discover and develop novel drug candidates targeting FTSJ1, a tRNA-modifying enzyme implicated in metastatic cancer cell survival. This is O2nix Bio’s first collaboration as an independent, privately funded commercial entity, building on its extensive research into biochemical mechanisms that regulate metastasis.
The collaboration will combine O2nix Bio’s proprietary biology platform and scientific leadership in tRNA methylation with Synfini’s AI Cloud Foundry, an end-to-end automated system that accelerates the design-make-test-analyze (DMTA) drug discovery cycle.
“We are thrilled to collaborate with the Synfini team,” said Elena Piskounova, Ph.D., founder and CEO of O2nix Bio. “Their chemistry automation platform, paired with our mechanistic insights into RNA modifications, will allow us to advance first-in-class therapies targeting cancer metastasis—which is responsible for over 90% of cancer-related deaths and still largely untreatable by current therapies.”
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com